An experimental compound called AP503 significantly strengthened bones in mice by activating GPR133, a receptor that boosts bone formation while slowing bone loss. Because the same treatment has also been linked to stronger muscles, researchers see intriguing potential for combating age-related decline and osteoporosis.
An experimental compound called AP503 significantly strengthened bones in mice by activating GPR133, a receptor that boosts bone formation while slowing bone loss.
Because the same treatment has also been linked to stronger muscles, researchers see intriguing potential for combating age-related decline and osteoporosis.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
An experimental compound called AP503 significantly strengthened bones in mice by activating GPR133, a receptor that boosts bone formation while slowing bone loss. Because the same treatment has also been linked to stronger muscles, researchers see intriguing potential for combating age-related decline and osteoporosis.
Open the app view to save this story, compare related coverage, and continue from the same source.